1 Study Matches
Site for LungMAP: A MASTER PROTOCOL TO EVALUATE BIOMARKER-DRIVEN THERAPIES AND IMMUNOTHERAPIES IN PREVIOUSLY-TREATED NON-SMALL CELL LUNG CANCER
This is a screening study and there is no treatment. The purpose of this study is to collect blood samples to determine if you are able to participate in other LUNGMAP studies.
Irina Geier at email@example.com
18 year(s) or older
Inclusion Criteria:pathologically proven non-small cell lung cancer
at least one line of systemic therapy for any stage of disease
Patients with known EGFR sensitizing mutations, EGFR T790M mutation, ALK gene fusion, ROS 1 gene rearrangement, or BRAF V600E
Patients must have Zubrod performance status 0-1
Patients must be ≥ 18 years of age.
Exclusion Criteria:Patients must be willing to provide prior smoking history as required on the LungMAP Onstudy Form.
Patients under age of 18
Criteria documentation within 28 days